Immuron Ltd — Regulatory Filings 2006

Nov 16, 2006

November 17th, 2006

Company Announcement Office Australian Stock Exchange Ltd (ASX) 4^th Floor, 20 Bridge Street Sydney NSW 2000

Dear Sir/Madam

Please find herewith a company announcement "Appointment Of Turkish Distributor" for release and distribution to the market immediately.

Yours sincerely

CONOR GRAHAM Managing Director & CEO

Eastern European Distributor appointed for Travelan Australian developed therapeutic set for European sales 2007

Australian biopharmaceutical company Anadis Limited (ASX:ANX) is pleased to announce the appointment of BIO–GEN Pharma as the Turkish and Eastern European distributor for Travelan. Located in Turkey, BIO-GEN Pharma has sales coverage to 150 pharmaceutical warehouses and over 15,000 pharmacies.

The Turkish and Eastern European Market

The Turkish population is well over 70 million and the country has had almost 18.5 million visitors, and over 3.2 million Turkish tourists departing between January and September this year (Turkish government figures). Medical statistics indicate approximately 40% of travellers will be somehow affected by Travellers' Diarrhoea, so market potential is significant.

BIO-GEN Pharma

BIO-GEN Pharma is a significant supplier to the Turkish market and offers a gateway for Travelan and other Anadis products to Eastern Europe. Sales coverage is expansive to 150 pharmaceutical warehouses, 15,000 pharmacies and all hospitals in Turkey. BIO-GEN has a team of 67 professional working through 3 distinct business units.

Visit www.bio-gen.net for more information.

Travelan - Natural and Effective

Travelan, a natural, clinically proven therapy is a revolutionary over-the-counter (OTC) preparation scientifically and clinically proven to significantly reduce the risk of getting the medical condition known as travellers' diarrhoea.

Travelan is prepared from naturally derived antibodies against 13 strains of E. coli that are the most common cause of travellers' diarrhoea. Travelan is high in antibodies that bind to certain intestinal bacteria and bacterial by-products, and is a not an antibiotic preparation - therefore not associated with the usual negative antibiotic side effects.

Travelan is a natural product that will enable travel with reduced fear of becoming ill due to exposure to E.coli bacteria. In hospital clinical trials in the US and Europe, Travelan has shown up to 90% protection against Enterotoxigenic E. coli (ETEC), the main cause of Travellers' Diarrhoea.

Potential Additional Gastrointestinal Indications for Travelan

Anadis will be investigating the use of Travelan for additional gastrointestinal therapeutic indications as a result of positive clinical feedback from a number of healthcare providers including medical specialists. This trial is set to begin very shortly, with details published to the market in the coming weeks.

Reports to the company indicate that a number of patients with a range of gastrointestinal conditions, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and ulcerative colitis, have experienced an improvement in some their symptoms (e.g. diarrhoea) whilst taking Travelan to reduce their risk of travellers' diarrhoea.

Travellers Diarrhoea

Travellers' diarrhoea (otherwise known as Delhi Belly, Montezuma's Revenge, Tourist Trots and The Flux etc) is described as the number one health problem for international travellers, in terms of frequency and economic impact. Travellers' diarrhoea is normally accompanied by other clinical features such as nausea, bloating, abdominal cramps and fever. Travelan significantly reduces the risk of being affected in the first instance.

Visit our websites: www.anadis.com.au and www.travelan.com

Anadis - Delivering On The Promise Of Biotechnology

About Anadis Limited:

Anadis, a Melbourne based biopharmaceutical company is focused on Nutraceutical and Pharmaceutical research and development. Anadis is a specialist in the development of bovine colostrum derived products for therapeutic use in humans. Projects include:

Anadis' first commercialised product: Travelan is a natural product, which significantly decrease the risk of the medical condition known as Travellers Diarrhoea and the symptoms of gastrointestinal disorders. Travelan is a colostrum preparation, against the common strains of $E_{\text{col}}i$ – the most common cause of Travellers.

Travelan has received a "Green Light' for sales in the US and a distributor in Canada has been appointed. Travelan is being considered for other markets including: Singapore, India, Korea, United Arab Emirates, Thailand, Malaysia. South Africa and the UK and EU.

Travelan has recently been potentially identified for additional gastrointestinal indications including Irritable Bowel Syndrome IBS and Inflammatory Bowel Disorder IBD.

For more information please visit www.travelan.com

EV-71 - a bioactive protein based preventative product against Enterovirus 71, a debilitating polio like disease, is one of the viruses that causes 'hand, foot and mouth' or 'slapped cheek' disease. A significant proportion of younger children effected can develop nervous signs such as fits, paralysis and Enterovirus 71 has the potentially to be fatal. Anadis is now preparing colostrum antibodies for commercialisation in an anti-EV71 preventative, set to begin marketing in Taiwan during the northern hemisphere summer of 2007.

A set of Bio-Defence and Respiratory Protection technologies, a project in conjunction with the Australian Department of Defence and US Bio-Defence Organisations, initially focused on short-term immediate protection from airborne bacteria such as Anthrax and Plague, future civilian applications include Hay Fever and Asthma.

This project is expanding to examine the use of antibodies in providing respiratory protection against Influenza virus

Bio-Shield 10 a range of "bio-shielding" technologies which protect delicate molecules, enzymes and proteins, initially targeted for use in the pro-biotic market.

Development into an Immune Stimulating Infant Formula is underway, initially destined for the Asian market.

Pyloran, which has been clinically proven to reduce levels of H.pylori bacteria in the stomach and reduce the symptoms of H.pylori associated gastritis - Anadis is also in early development of a H.pylori vaccine.

For further information, please contact:

Conor Graham - Chief Executive Officer Email: $conor.g@anadis.com.au$ +61 3 9358 6388 Arie Nudel - Investor Relations Email: arie.n@anadis.com.au +61 3 9358 6388